© 1995 Oxford University Press
research-article |
Uptake and distribution of N-acetylcysteine in mice: tissue-specific effects on glutathione concentrations
Biomedical Research Centre, University of Dundee, Ninewells Hospital and Medical School Dundee DD1 9SY
1CRC Department of Medical Oncology, University of Glasgow Alexander Stone Building, Garscube Estate, Switchback Road, Bearsden, Glasgow G61 1BD
2Syntex Research Centre, Research Park, Heriot-Watt University Riccarton, Edinburgh EH14 4AP
3University of Edinburgh, Institute of Cell, Animal and Population Biology, Ashworth Laboratories West Mains Road, Edinburgh EH9 3JT
4Imperial Cancer Research Fund Molecular Pharmacology Unit, Biomedical Research Centre, Ninewells Hospital and Medical School Dundee DD1 9SY, UK
5To whom correspondence should be addressed
Modulation of cellular thiols has been used to ameliorate the toxic side effects associated with cancer chemotherapy and is currently being investigated as a novel therapeutic strategy in cancer treatment. One of the most extensively studied modulators of thiol levels is N-acetylcysteine (NAC), a cytoprotective drug with multiple therapeutic applications, including use as an adjunct to cancer chemotherapy. Tissue-specific protective effects have previously been observed when NAC has been used in conjunction with chemotherapeutic alkylating agents, but the basis for this was unknown. In view of the contrasting cytoprotective effects of NAC in bladder and bone marrow we examined the effect of this compound on mouse liver, bladder and bone marrow glutathione (GSH) levels, as well as the disposition of 14C-labelled NAC. Radiolabelled NAC was taken up by the majority of tissues at varying rates and levels, except for the brain and spinal cord. The bladder, bone marrow and liver all took up the drug or its metabolites within 15 min of injection. NAC was not found to alter GSH concentrations in the liver, but increased GSH levels in the bladder 
2-fold. In contrast, the GSH content of bone marrow was found to decrease by 70–50% after NAC administration. When separate bone marrow cell populations were examined the decrease in GSH was associated with granulocytes, as opposed to lymphocytes, whose GSH levels remained unchanged. These findings provide a possible explanation for the differential cytoprotective effects of NAC.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. L. Martin and P. Teismann Glutathione--a review on its role and significance in Parkinson's disease FASEB J, October 1, 2009; 23(10): 3263 - 3272. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. Martin, M. P. Jokinen, H. P. Honeycutt, A. Quinn, F. W. Kari, J. C. Barrett, and J. E. French Tumor Profile of Novel p53 Heterozygous Tg.AC (v-Ha-ras) Bitransgenic Mice Treated with Benzo(a)pyrene and Fed Dietary N-acetyl-L-cysteine (NAC) Toxicol. Sci., October 1, 2004; 81(2): 293 - 301. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Arfsten, E. W. Johnson, A. R. Thitoff, A. E. Jung, E. R. Wilfong, S. M. Lohrke, T. A. Bausman, J. S. Eggers, and A. J. Bobb Impact of 30-Day Oral Dosing with N-acetyl-L-cysteine on Sprague-Dawley Rat Physiology International Journal of Toxicology, July 1, 2004; 23(4): 239 - 247. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Neuwelt, M. A. Pagel, D. F. Kraemer, D. R. Peterson, and L. L. Muldoon Bone Marrow Chemoprotection without Compromise of Chemotherapy Efficacy in a Rat Brain Tumor Model J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 594 - 599. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Fishbane, J. H. Durham, K. Marzo, and M. Rudnick N-Acetylcysteine In The Prevention Of Radiocontrast-Induced Nephropathy J. Am. Soc. Nephrol., February 1, 2004; 15(2): 251 - 260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Medved, M. J. Brown, A. R. Bjorksten, J. A. Leppik, S. Sostaric, and M. J. McKenna N-acetylcysteine infusion alters blood redox status but not time to fatigue during intense exercise in humans J Appl Physiol, April 1, 2003; 94(4): 1572 - 1582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. J. Van Schooten, A. Besarati Nia, S. De Flora, F. D'Agostini, A. Izzotti, A. Camoirano, A. J. M. Balm, J. W. Dallinga, A. Bast, G. R. M. M. Haenen, et al. Effects of Oral Administration of N-Acetyl-L-cysteine: A Multi-Biomarker Study in Smokers Cancer Epidemiol. Biomarkers Prev., February 1, 2002; 11(2): 167 - 175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Neuwelt, M. A. Pagel, B. P. Hasler, T. G. Deloughery, and L. L. Muldoon Therapeutic Efficacy of Aortic Administration of N-Acetylcysteine as a Chemoprotectant against Bone Marrow Toxicity after Intracarotid Administration of Alkylators, with or without Glutathione Depletion in a Rat Model Cancer Res., November 1, 2001; 61(21): 7868 - 7874. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Efferth, U. Fabry, and R. Osieka DNA damage and apoptosis in mononuclear cells from glucose-6-phosphate dehydrogenase-deficient patients (G6PD Aachen variant) after UV irradiation J. Leukoc. Biol., March 1, 2001; 69(3): 340 - 342. [Abstract] [Full Text]
|
|
|
|
|
|
H. KAMENCIC, R. W. GRIEBEL, A. W. LYON, P. G. PATERSON, and B. H. J. JUURLINK Promoting glutathione synthesis after spinal cord trauma decreases secondary damage and promotes retention of function FASEB J, January 1, 2001; 15(1): 243 - 250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Balansky, F. D' Agostini, and S. De Flora Induction, persistence and modulation of cytogenetic alterations in cells of smoke-exposed mice Carcinogenesis, August 1, 1999; 20(8): 1491 - 1498. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Han, C. K. Sen, S. Roy, M. S. Kobayashi, H. J. Tritschler, and L. Packer Protection against glutamate-induced cytotoxicity in C6 glial cells by thiol antioxidants Am J Physiol Regulatory Integrative Comp Physiol, November 1, 1997; 273(5): R1771 - R1778. [Abstract] [Full Text] [PDF]
|
|